Cytokinetics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Cytokinetics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-14.7%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-14.7%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being

May 09

Cytokinetics, Incorporated: Buyout Speculation Persists

Apr 01

Cytokinetics: CEO Talks Down Buyout Prospects

Mar 16

Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)

Jan 12

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CYTK şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: CYTK şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Cytokinetics Piyasaya Karşı Temettü Getirisi

CYTK temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CYTK)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (CYTK) (3 yıla kadar)	0%

Önemli Temettü: CYTK şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CYTK şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: CYTK şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: CYTK herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Cytokinetics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Consensus revenue estimates increase by 47%, EPS downgraded

Cytokinetics, Incorporated Presents Additional Data from GALACTIC-HF At the American Heart Association Scientific Sessions 2024

Cytokinetics, Incorporated Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy At the American Heart Association Scientific Sessions 2024

Cytokinetics, Incorporated Presents Additional Data from GALACTIC-HF At the American Heart Association Scientific Sessions 2024

Cytokinetics: On The Cusp Of Commercialization

Consensus revenue estimates fall by 14%

Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4015089

Now 20% overvalued after recent price rise

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Insider notifies of intention to sell stock

Cytokinetics, Incorporated to Report Q3, 2024 Results on Nov 06, 2024

Insider notifies of intention to sell stock

Cytokinetics Presents Additional Data from EQUOIA-HCM At the HCMS Scientific Sessions

Consensus revenue estimates decrease by 23%

Cytokinetics, Incorporated Presents Additional Data from SEQUOIA-HCM at the European Society of Cardiology Congress 2024

Insider notifies of intention to sell stock

Consensus revenue estimates fall by 54%

CEO, President & Director notifies of intention to sell stock

Cytokinetics: Aficamten Rolling NDA Submission Leads To Expansion Opportunities

Is Cytokinetics (NASDAQ:CYTK) Weighed On By Its Debt Load?

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

CEO, President & Director notifies of intention to sell stock

Cytokinetics, Incorporated to Report Q2, 2024 Results on Aug 08, 2024

Cytokinetics' Aficamten: Heartfelt Potential Amid Market Woes

CEO, President & Director recently sold US$622k worth of stock

Consensus revenue estimates increase by 10%

CEO, President & Director recently sold US$1.2m worth of stock

Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants

CEO, President & Director notifies of intention to sell stock

VP & Chief Accounting Officer recently sold US$636k worth of stock

New minor risk - Insider selling

Cytokinetics, Incorporated announced that it has received $49.999992 million in funding from Royalty Pharma Development Funding, LLC

Price target decreased by 7.5% to US$86.06

Consensus revenue estimates increase by 41%

Cytokinetics Decides To Go It Alone

Cytokinetics, Incorporated has completed a Follow-on Equity Offering in the amount of $500.000022 million.

Consensus revenue estimates decrease by 13%

Cytokinetics, Incorporated Announces Resignation of Sandford D. Smith as Board of Directors

Insider notifies of intention to sell stock

Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being

Cytokinetics, Incorporated Announces CEDAR-HCM Is Open to Enrollment

Consensus revenue estimates decrease by 12%

Independent Chairman notifies of intention to sell stock

Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024

Cytokinetics, Incorporated to Report Q1, 2024 Results on May 08, 2024

Insider exercised options and sold US$1.9m worth of stock

Cytokinetics, Incorporated, Annual General Meeting, May 15, 2024

Cytokinetics Presents Additional 48-Week Data from Forest-Hcm, the Open Label Extension Clinical Study of Aficamten, At the American College of Cardiology 73rd Annual Scientific Session

Cytokinetics, Incorporated: Buyout Speculation Persists

Cytokinetics: CEO Talks Down Buyout Prospects

Insider notifies of intention to sell stock

Consensus revenue estimates decrease by 49%, EPS upgraded

Cytokinetics, Incorporated Provides Revenue Guidance for 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Cytokinetics, Incorporated to Report Q4, 2023 Results on Feb 27, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw, Senior Vice President, Effective February 23, 2024

CEO, President & Director notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Pursuit of Cytokinetics Reportedly Cools

Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

CEO, President & Director notifies of intention to sell stock

Cytokinetics, Incorporated Announces Positive Results from Sequoia-Hcm, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy

New major risk - Revenue and earnings growth

Price target increased by 20% to US$74.39

CEO, President & Director notifies of intention to sell stock

Cytokinetics Presents Results from COURAGE-ALS At the 34th International Symposium on ALS/MND

Now 23% undervalued after recent price drop

CEO, President & Director exercised options and sold US$329k worth of stock

Insufficient new directors

CEO, President & Director notifies of intention to sell stock